Balance Sheet StrengthA very low debt-to-equity ratio indicates conservative leverage and a solid equity base. That durability supports funding operations, R&D or tender participation without raising excessive debt, giving the business financial flexibility to navigate healthcare cycles over months to years.

Improving Cash GenerationRising free cash flow and a high operating cash flow-to-net income ratio show stronger cash conversion versus earnings. This improves the company’s ability to self-fund maintenance capex, service contracts and selective investment, enhancing resilience and strategic optionality.

Defensible Product & Market MixA diversified device portfolio across hospital, home and outpatient channels plus recurring service and tender revenue creates multiple durable revenue streams. That mix supports steady demand and mitigates reliance on any single channel or short-term market fluctuation.

Bears Say

Declining Revenue GrowthMaterial year-over-year revenue contraction signals persistent demand or market-share weakness. Sustained top-line decline makes it harder to leverage fixed costs, constrains reinvestment capacity and raises the bar for management to restore organic growth over the medium term.

Compressing Gross MarginsA falling gross margin implies pricing pressure or rising input costs and erodes operating leverage. Over months this compresses operating profit potential and increases reliance on volume recovery or cost restructuring to sustain net margins and fund strategic initiatives.

Suboptimal FCF ConversionFCF lagging net income means earnings are not fully translating into spendable cash, limiting internal funding for growth, dividends or debt repayment. This structural conversion gap could constrain capital allocation flexibility if persistent over coming quarters.

GME FAQ

What was Geratherm Medical AG’s price range in the past 12 months?

Geratherm Medical AG lowest stock price was €2.48 and its highest was €7.88 in the past 12 months.

What is Geratherm Medical AG’s market cap?

Geratherm Medical AG’s market cap is €14.97M.

When is Geratherm Medical AG’s upcoming earnings report date?

Geratherm Medical AG’s upcoming earnings report date is Apr 29, 2026 which is in 70 days.

How were Geratherm Medical AG’s earnings last quarter?

Geratherm Medical AG released its earnings results on Aug 28, 2025. The company reported -€0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.03.

Is Geratherm Medical AG overvalued?

According to Wall Street analysts Geratherm Medical AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Geratherm Medical AG pay dividends?

Geratherm Medical AG pays a Annually dividend of €0.1 which represents an annual dividend yield of 3.46%. See more information on Geratherm Medical AG dividends here

What is Geratherm Medical AG’s EPS estimate?

Geratherm Medical AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Geratherm Medical AG have?

Geratherm Medical AG has 5,444,998 shares outstanding.

What happened to Geratherm Medical AG’s price movement after its last earnings report?

Geratherm Medical AG reported an EPS of -€0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Geratherm Medical AG?

Currently, no hedge funds are holding shares in DE:GME

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Geratherm Medical Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

8.35%

Trailing 12-Months

Asset Growth

-18.19%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Geratherm Medical AG

Geratherm Medical AG operates as a medical technology company in Germany. It operates through Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems segments. The Healthcare Diagnostic segment provides clinical thermometers; blood pressure monitors; and self-test diagnostic products for women, including pregnancy tests, chlamydia tests, urinary tract infections, diverse ovulation test solutions, and pH tests. The Respiratory segment develops and manufactures products primarily for pulmonary and cardiopulmonary function diagnostics. The Medical Warming Systems segment offers MRI-compatible incubators for premature and newborn infants under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation. The company markets its products through pharmacies, hospitals, and clinics. It exports its products to approximately 60 countries. The company was founded in 1990 and is headquartered in Geschwenda, Germany.